Association between pioglitazone use and bladder cancer: A systematic review
Sujatha Baddam, Amulya Varshini Banka, Shravani Divity, Maharshikumar Sandesara, Yethindra Vityala · 2024
Read Association between pioglitazone use and bladder cancer: A systematic review by Sujatha Baddam, Amulya Varshini Banka, Shravani Divity, Maharshikumar Sandesara, Yethindra Vityala (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11810689.txt.
Description
Sujatha Baddam and co-authors review whether the diabetes drug pioglitazone raises the risk of bladder cancer. Their review appeared in 2024. Bladder cancer rates vary widely by place, sex, and wealth, and a drug link has long been debated. The team searched three databases for studies from 2018 to mid-2024. From 212 candidate papers, screening left six that met the rules and had usable data.
Two of the six found a possible link between the drug and higher cancer risk; four found no clear tie. The authors say the split verdict means the question stays open. They call for studies that handle confounders better, especially how long patients took the drug and who the patients were. Until then, they advise care rather than alarm in prescribing.
Catalog record
| CREATOR | Sujatha Baddam, Amulya Varshini Banka, Shravani Divity, Maharshikumar Sandesara, Yethindra Vityala |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 27 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |